Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma
Por:
Trilla-Fuertes L., Gámez-Pozo A., Prado-Vázquez G., López-Vacas R., Zapater-Moros A., López-Camacho E., Lumbreras-Herrera M.I., Soriano V., Garicano F., Lecumberri M.J., de la Borbolla, MR, Majem M., Pérez-Ruiz E., González-Cao M., Oramas J., Magdaleno A., Fra J., Martín-Carnicero A., Corral M., Puértolas T., Ramos R., Vara, JAF, Espinosa E.
Publicada:
2 ene 2023
Ahead of Print:
2 ene 2023
Resumen:
Immunotherapy based on anti-PD1 antibodies has improved the outcome of advanced melanoma. However, prediction of response to immunotherapy remains an unmet need in the field. Tumor PD-L1 expression, mutational burden, gene profiles and microbiome profiles have been proposed as potential markers but are not used in clinical practice. Probabilistic graphical models and classificatory algorithms were used to classify melanoma tumor samples from a TCGA cohort. A cohort of patients with advanced melanoma treated with PD-1 inhibitors was also analyzed. We established that gene expression data can be grouped in two different layers of information: immune and molecular. In the TCGA, the molecular classification provided information on processes such as epidermis development and keratinization, melanogenesis, and extracellular space and membrane. The immune layer classification was able to distinguish between responders and non-responders to immunotherapy in an independent series of patients with advanced melanoma treated with PD-1 inhibitors. We established that the immune information is independent than molecular features of the tumors in melanoma TCGA cohort, and an immune classification of these tumors was established. This immune classification was capable to determine what patients are going to respond to immunotherapy in a new cohort of patients with advanced melanoma treated with PD-1 inhibitors Therefore, this immune signature could be useful to the clinicians to identify those patients who will respond to immunotherapy.
Filiaciones:
Trilla-Fuertes L.:
Hosp Univ La Paz IdiPAZ, Mol Oncol Lab, Madrid 28046, Spain
Gámez-Pozo A.:
Hosp Univ La Paz IdiPAZ, Mol Oncol Lab, Madrid 28046, Spain
Biomed Mol Med SL, Madrid 28049, Spain
Prado-Vázquez G.:
Hosp Univ La Paz IdiPAZ, Mol Oncol Lab, Madrid 28046, Spain
Biomed Mol Med SL, Madrid 28049, Spain
López-Vacas R.:
Hosp Univ La Paz IdiPAZ, Mol Oncol Lab, Madrid 28046, Spain
Zapater-Moros A.:
Hosp Univ La Paz IdiPAZ, Mol Oncol Lab, Madrid 28046, Spain
Biomed Mol Med SL, Madrid 28049, Spain
López-Camacho E.:
Biomed Mol Med SL, Madrid 28049, Spain
Lumbreras-Herrera M.I.:
Hosp Univ La Paz IdiPAZ, Mol Oncol Lab, Madrid 28046, Spain
Soriano V.:
Inst Valenciano Oncol, Valencia 46009, Spain
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Garicano F.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Galdakao, Bizkaia 48960, Spain
Lecumberri M.J.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Complejo Hosp Navarra, Pamplona 31008, Spain
de la Borbolla, MR:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Valme, Seville 41014, Spain
Majem M.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Santa Creu & Sant Pau, Barcelona 08025, Spain
Pérez-Ruiz E.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Costa Sol, Marbella 29603, Spain
González-Cao M.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Quiron Dexeus, Barcelona 08028, Spain
Oramas J.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Univ Canarias San Cristobal Laguna, San Cristobal la Laguna 38320, Spain
Magdaleno A.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Univ Elche & Vega Baja, Elche 03203, Spain
Fra J.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Univ Rio Hortega, Valladolid 47012, Spain
Martín-Carnicero A.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp San Pedro, Logrono 26006, Spain
Corral M.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Clin Lozano Blesa, Zaragoza 50009, Spain
Puértolas T.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
Hosp Univ Miguel Servet, Zaragoza 50009, Spain
Ramos R.:
Genom Unit, Parque Cientif Madrid, Madrid 28049, Spain
Vara, JAF:
Hosp Univ La Paz IdiPAZ, Mol Oncol Lab, Madrid 28046, Spain
Biomed Mol Med SL, Madrid 28049, Spain
ISCIII, CIBERONC, Madrid 28029, Spain
Espinosa E.:
Spanish Melanoma Grp GEM, Barcelona 08024, Spain
ISCIII, CIBERONC, Madrid 28029, Spain
Hosp Univ La Paz, Med Oncol Serv, Madrid 28046, Spain
gold, Green Published, All Open Access, Gold, Green
|